Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
104 participants
INTERVENTIONAL
2021-08-01
2026-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Translation and Clinical Implementation of a Test of Language and Short-term Memory in Aphasia
NCT03635554
Neurobiology of Language Recovery in Aphasia: Natural History and Treatment-Induced Recovery
NCT01927302
Conversation Group Treatment for Aphasia: Does it Work?
NCT05113160
Theory-Driven Treatment of Language and Cognitive Processes in Aphasia
NCT02664506
Web-Based Treatment for Aphasia
NCT04413136
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Structural priming training
Participants will be enrolled in 3 sessions of structural priming training (for experiment 1-3) or up to 15 treatment sessions (for experiment 4). Each session will be about 2 hour long, consisting of a set of tasks, including repeating, making, and remembering various types of sentences. In experiment 1-3, each participant will receive two different experimental priming conditions that are being compared within each session. In experiment 4, participants will receive a structural priming treatment in a single-subject design.
Sentence training
Participants will be trained to read, make, and recall sentences during each session.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sentence training
Participants will be trained to read, make, and recall sentences during each session.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 6 months post-onset of eft hemisphere stroke
* Native speaker of English
* Normal or corrected to normal hearing and vision
* High-school educated
* Difficulty communicating in sentences, with some ability to use words independently
Exclusion Criteria
* Other neurological conditions affecting communication (e.g., dementia)
* Uncontrolled psychiatric/psychological conditions affecting thinking and communication
* Active alcohol/substance abuse
21 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Temple University
OTHER
University of California, San Diego
OTHER
Purdue University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ji Yeon Lee
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jiyeon Lee, PhD
Role: PRINCIPAL_INVESTIGATOR
Purdue University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Purdue University
West Lafayette, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-2021-659
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.